National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007
- PMID: 20855045
- PMCID: PMC2952543
- DOI: 10.1016/j.jaac.2010.07.007
National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007
Abstract
Objective: To examine patterns and recent trends in multiclass psychotropic treatment among youth visits to office-based physicians in the United States.
Method: Annual data from the 1996-2007 National Ambulatory Medical Care Surveys were analyzed to examine patterns and trends in multiclass psychotropic treatment within a nationally representative sample of 3,466 child and adolescent visits to office-based physicians in which a psychotropic medication was prescribed.
Results: There was an increase in the percentage of child visits in which psychotropic medications were prescribed that included at least two psychotropic classes. Across the 12 year period, multiclass psychotropic treatment rose from 14.3% of child psychotropic visits (1996-1999) to 20.2% (2004-2007) (adjusted odds ratio [AOR] = 1.89, 95% confidence interval [CI] = 1.22-2.94, p < .01). Among medical visits in which a current mental disorder was diagnosed, the percentage with multiclass psychotropic treatment increased from 22.2% (1996-1999) to 32.2% (2004-2007) (AOR = 2.23, 95% CI = 1.42-3.52, p < .001). Over time, there were significant increases in multiclass psychotropic visits in which ADHD medications, antidepressants, or antipsychotics were prescribed, and a decrease in those visits in which mood stabilizers were prescribed. There were also specific increases in co-prescription of ADHD medications and antipsychotic medications (AOR = 6.22, 95% CI = 2.82-13.70, p < .001) and co-prescription of antidepressant and antipsychotic medications (AOR = 5.77, 95% CI = 2.88-11.60, p < .001).
Conclusions: Although little is known about the safety and efficacy of regimens that involve concomitant use of two or more psychotropic agents for children and adolescents, multiclass psychotropic pharmacy is becoming increasingly common in outpatient practice.
Copyright © 2010 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Figures
Similar articles
-
National trends in psychotropic medication polypharmacy in office-based psychiatry.Arch Gen Psychiatry. 2010 Jan;67(1):26-36. doi: 10.1001/archgenpsychiatry.2009.175. Arch Gen Psychiatry. 2010. PMID: 20048220
-
Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder.Arch Pediatr Adolesc Med. 1999 Dec;153(12):1257-63. doi: 10.1001/archpedi.153.12.1257. Arch Pediatr Adolesc Med. 1999. PMID: 10591302
-
Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties.JAMA. 1998 Feb 18;279(7):526-31. doi: 10.1001/jama.279.7.526. JAMA. 1998. PMID: 9480363
-
Challenges and Promises of Pediatric Psychopharmacology.Acad Pediatr. 2016 Aug;16(6):508-18. doi: 10.1016/j.acap.2016.03.011. Epub 2016 Apr 5. Acad Pediatr. 2016. PMID: 27064142 Review.
-
[Guidelines for the prescription of mood stabilizers for adolescents: A literature review].Encephale. 2017 Oct;43(5):464-470. doi: 10.1016/j.encep.2016.09.005. Epub 2016 Nov 18. Encephale. 2017. PMID: 27871720 Review. French.
Cited by
-
Editorial: Psychotropic overprescribing to youth: scope of the problem, causes, and possible solutions.Front Psychiatry. 2024 May 6;15:1418600. doi: 10.3389/fpsyt.2024.1418600. eCollection 2024. Front Psychiatry. 2024. PMID: 38774431 Free PMC article. No abstract available.
-
Antipsychotics in child and adolescent patients with major depressive disorder: A retrospective analysis of prescribing patterns.Ment Health Clin. 2024 Feb 1;14(1):10-16. doi: 10.9740/mhc.2024.02.010. eCollection 2024 Feb. Ment Health Clin. 2024. PMID: 38312444 Free PMC article.
-
Increased Prescribing of Psychotropic Drugs or School-Based Services for Children with Disabilities? Associations of These Self-control-Boosting Strategies with Juvenile Violence at the State Level.J Dev Life Course Criminol. 2023 Feb 9:1-35. doi: 10.1007/s40865-023-00223-4. Online ahead of print. J Dev Life Course Criminol. 2023. PMID: 36789240 Free PMC article.
-
Agreement between actigraphy and sleep diaries: A 28-day real-time monitoring study among suicidal adolescents following acute psychiatric care.J Psychosom Res. 2023 Jan;164:111097. doi: 10.1016/j.jpsychores.2022.111097. Epub 2022 Nov 17. J Psychosom Res. 2023. PMID: 36455300 Free PMC article.
-
Use of central nervous system drugs in combination with selective serotonin reuptake inhibitor treatment: A Bayesian screening study for risk of suicidal behavior.Front Psychiatry. 2022 Nov 9;13:1012650. doi: 10.3389/fpsyt.2022.1012650. eCollection 2022. Front Psychiatry. 2022. PMID: 36440412 Free PMC article.
References
-
- AACAP Work Group on Quality Issues. Practice parameter on the use of psychotropic medication in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2009;48:961–973. - PubMed
-
- Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2002;40:168–179. - PubMed
-
- Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;297:1683–1696. - PubMed
-
- TADS Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescetns with Depression Study (TADS) randomized controlled trial. JAMA. 2004;292:807–820. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
